SAN FRANCISCO, CA, March 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced that the Company will hold a quarterly conference call to discuss its fourth quarter and year end 2022 financial results on Friday March 24th, 2023 at 1:00 pm ET / 10:00 am PT. The fourth quarter and year end 2022 financial results press release will be issued before the market open on Friday March 24th, 2023.
Teleconference Date/Time
Friday March 24th, 2023 at 1:00 pm ET / 10:00 am PT
Teleconference and Webcast Information
To participate, please call 1 (844) 413-3972 at least 10 minutes prior to the start of the call and ask to join the American Shared Hospital Services call.
A simultaneous webcast of the call may be accessed through the Company's website, www.ashs.com, or at www.streetevents.com for institutional investors.
A replay of the call will be available at 1 (877) 344-7529, access code 7388246, through March 31, 2023. The call will also be available for replay on the Company’s website, www.ashs.com, for one year.
About American Shared Hospital Services (NYSE American: AMS)
American Shared Hospital Services is a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services. AMS is a world leader in providing Gamma Knife radiosurgery equipment, a non-invasive treatment for malignant and benign brain tumors, vascular malformations, and trigeminal neuralgia (facial pain). The Company also offers proton therapy, and the latest IGRT, IMRT and MR/LINAC systems. For more information, please visit: www.ashs.com.
Contacts:
American Shared Hospital Services
Ray Stachowiak
Executive Chairman
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations
PCG Advisory
Stephanie Prince
(646) 863-6341
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$3.14 |
| Daily Change: | -0.02 -0.63 |
| Daily Volume: | 4,013 |
| Market Cap: | US$19.970M |
August 14, 2024 November 20, 2023 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
